Compare INDP & SLE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INDP | SLE |
|---|---|---|
| Founded | 2000 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Services-Misc. Amusement & Recreation |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.2M | 5.6M |
| IPO Year | 2021 | 2019 |
| Metric | INDP | SLE |
|---|---|---|
| Price | $1.14 | $4.58 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $60.00 |
| AVG Volume (30 Days) | 38.0K | ★ 1.1M |
| Earning Date | 05-11-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,064,000.00 |
| Revenue This Year | N/A | $24.86 |
| Revenue Next Year | N/A | $49.77 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 90.41 |
| 52 Week Low | $0.27 | $0.10 |
| 52 Week High | $13.24 | $11.43 |
| Indicator | INDP | SLE |
|---|---|---|
| Relative Strength Index (RSI) | 27.50 | 51.39 |
| Support Level | N/A | $3.40 |
| Resistance Level | $2.08 | $4.89 |
| Average True Range (ATR) | 0.23 | 0.61 |
| MACD | -0.11 | 0.07 |
| Stochastic Oscillator | 17.79 | 23.94 |
Indaptus Therapeutics Inc is a clinical biotechnology company that has developed a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. Its approach is based on the hypothesis that efficient activation of both innate and adaptive immune cells and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system activating signals that can be administered safely intravenously. Its patented technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria, designed to have reduced i.v. toxicity, but largely uncompromised ability to prime or activate many of the cellular components of innate and adaptive immunity. Its candidate, Decoy20 is for patients with solid tumors.
Super League Enterprise Inc is the rocket ship to the metaverse. It is a creator and publisher of content experiences and media solutions across the globe's immersive platforms. Its solutions provide incomparable access to massive audiences that gather in immersive digital spaces to socialize, play, explore, collaborate, shop, learn, and create. The company offers a complete range of development, distribution, monetization, and optimization capabilities designed to engage users through dynamic, energized programs. It generates revenue from advertising, including immersive game world and experience publishing and in-game media products, direct-to-consumer offers, including in-game items, e-commerce, game passes and ticketing and digital collectibles, and content and technology.